Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center’s experience

References

• Donnelly JP, Hanna M. Cardiac amyloidosis: an update on diagnosis and treatment. Cleve Clin J Med. 2017;84:12–26.
   PubMed Web of Science ®Google Scholar
• Palha JA. Transthyretin as a thyroid hormone carrier: function revisited. Clin Chem Lab Med. 2002;40:1292–1300.
   PubMed Web of Science ®Google Scholar
• McKinnon B, Li H, Richard K, et al. Synthesis of thyroid hormone binding proteins transthyretin and albumin by human trophoblast. J Clin Endocrinol Metab. 2005;90:6714–6720.
   PubMed Web of Science ®Google Scholar
• Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol. 2016;214:477–481.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Yoshida K, Tokuda T, et al. Familial transthyretin amyloidosis. 2001 Nov 5 [Updated 2012 Jan 26]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2017. Available from: https://www-ncbi-nlm-nih-gov.ccmain.ohionet.org/books/NBK1194/.
   Google Scholar
• Hanna M. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep. 2014;11:50–57.
   PubMedGoogle Scholar
• Vranian MN, Sperry BW, Valent J, et al. Emerging advances in the management of cardiac amyloidosis. Curr Cardiol Rep. 2015;17:100.
   PubMed Web of Science ®Google Scholar
• Alexander KM, Singh A, Falk RH. Novel pharmacotherapies for cardiac amyloidosis. Pharmacol Ther. 2017;180:129–138.
   PubMed Web of Science ®Google Scholar
• Sperry BW, Tang WHW. Amyloid heart disease: genetics translated into disease-modifying therapy. Heart. 2017;103:812–817.
   PubMed Web of Science ®Google Scholar
• Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001;293:2459–2462.
   PubMed Web of Science ®Google Scholar
• Hammarström P, Wiseman RL, Powers ET, et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 2003;299:713–716.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006;13:236–249.
   PubMed Web of Science ®Google Scholar
• Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004;84:545–552.
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, Diflunisal Trial Consortium, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–2667.
   PubMed Web of Science ®Google Scholar
• Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169:141–149.
   PubMed Web of Science ®Google Scholar
• Castaño A, Helmke S, Alvarez J, et al. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail. 2012;18:315–319.
   PubMedGoogle Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–2412.
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Hernández-Díaz S. Nonsteroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003;14:240–246.
   PubMed Web of Science ®Google Scholar
• Arfè A, Scotti L, Varas-Lorenzo C, et al. Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. Bmj. 2016;354:i4857.
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093–2099.
   PubMed Web of Science ®Google Scholar
• Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med. 1992;327:749–754.
   PubMed Web of Science ®Google Scholar
• Dolobid (diflunisal) [package insert]. Merck & Co., Inc., Whitehouse Station, NJ; 1988.
   Google Scholar
• Sekijima Y, Tojo K, Morita H, et al. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid. 2015;22:79–83.
   PubMed Web of Science ®Google Scholar
• Sperry BW, Vranian MN, Hachamovitch R, et al. Subtype-specific interactions and prognosis in cardiac amyloidosis. J Am Heart Assoc. 2016;5:e002877
   PubMed Web of Science ®Google Scholar
• Buxbaum J, Jacobson DR, Tagoe C, et al. Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol. 2006;47:1724–1725.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39:2799–2806.
   PubMed Web of Science ®Google Scholar
• Rosenblum H, Castaño A, Alvarez J, et al. TTR (transthyretin) stabilizers are associated with improved survival in patients with ttr cardiac amyloidosis. Circ Heart Fail. 2018;11:e004769.
   PubMed Web of Science ®Google Scholar
• Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy [news release]. New York, NY: Pfizer Inc Media Relations; 2018 Mar 29 [cited 2018 Jul 9]. http://press.pfizer.com/press-release/pfizer-announces-positive-topline-results-phase-3-attr-act-study-tafamidis-patients-tr.
   Google Scholar